Mirum Pharmaceuticals is trading at $75.00, down 19.97% in after-hours trading; no reliable report identifies a specific catalyst. - The November 6 GeneDx collaboration announced no-cost genetic testing for eligible patients; available reporting does not link it to the sell-off. - November 3 third-quarter results and raised sales guidance are prior context, not a confirmed explanation. - Major indexes were mixed-to-positive in the supplied market context, which does not clearly explain the stock-specific drop.